John Kelley CEO of CereScan

CereScan’s Kelley To Share His Unique Insights Into Unlocking The Mysteries Of The Human Brain As Panelist At Singularity University’s Global Forum

John Kelley, Chairman and CEO of CereScan®, will inject his inimitable style and passion for the plight of sufferers of chronic brain disorders when he addresses Singularity University’s Global Forum as a member of the Breakthrough Braintech Panel on August 15, 2017 in San Francisco. Kelley will join other innovators in discussing the connection between our biology and our inner selves and finding ways to exponentially improve our mental health.

The Global Forum is Singularity University’s flagship event and boasts a world-class collection of thinkers, leaders and doers who have come together to educate, influence and inspire others on the front lines of technical innovation.

“The chance to meet and collaborate with so many individuals who are trailblazers and barrier busters in the fields of technology and mental health is certainly my honor and privilege,” said Kelley. “The Global Forum provides a unique opportunity for us front line warriors to exchange ideas on emerging technologies and help change the direction and pace of global health.”

Featured prominently in Kelley’s presentation is CereScan’s recently unveiled CereMetrix® data analytics platform, which provides decision support and cohort analysis to medical professionals and researchers involved in diagnosing and identifying abnormalities in the human brain. CereMetrix® is a multi-variable search engine and correlative tool to support research and diagnostic applications. Through its patented neuroimaging database systems and methods, the platform is designed to accelerate the accurate and effective diagnosis of complex brain-related disorders, improving treatment and outcomes for patients.

The key attributes of CereMetrix include:

  • Unique, medical database for diagnosing complex brain-related disorders based on HD functional imagery and voxel level analysis
  • Provide a highly accurate, statistically valid standardized normative dataset for comparison and correlation of related symptomology
  • Proprietary software, scalable platform, with advanced intelligence and predicative analytics capabilities
  • Robust capabilities and easy to use
  • Accelerate accurate and effective diagnosis across the range of complex brain disorders
  • Enable appropriate diagnosis and treatment

About CereScan®

CereScan® combines state-of-the-art brain imaging technologies with a patient-centered model of care to provide the highest level of neuro-diagnostics available. CereScan utilizes state-of-the-art gamma camera technology, new generation imaging software and a proprietary process to produce comprehensive medical reports including voxel level images of brain function and physiology. Our functional brain imaging technologies are the most sophisticated in the world today. Additional information about the company is available at https://cerescan.com.

CereScan® and CereMetrix® are registered trademark of CereHealth Corp.

Contacts

RAM Communications
Ron Margulis, 908-272-3930
ron@rampr.com

Medical innovation and progress don’t have to stop under tight federal budgets

 

Budget Planning

There has been a lot of discussion about Pres. Trump’s first budget submission, particularly in healthcare channels, leading to more questions than answers. Will Medicaid really be cut by billions of dollars? Are certain research programs and pharmaceutical regulations destined for the scrap heap? Will the CDC and NIH have their budgets slashed? The list goes on.

There is an excellent article in The Atlantic that provides insight into the impact of the budget on healthcare, much of which is negative for many of us in the sector. Instead of reviewing the downside, I want to focus on the opportunities and trend away from simply piling on regarding the issue the proposed budget cuts will create. These opportunities arise from having to make difficult choices based on fewer resources available to address specific challenges. It may sound counter-intuitive, but those choices over diminished fund allocations can actually lead to dramatic advancement of research in health and diagnostics.

How?

The traditional path to innovation in healthcare is for researchers to receive money from the government and other sources, develop a solution to a specific medical challenge, seek approval from governmental bodies and then endeavor to commercialize the pharmaceutical device or process. The creative way to bring innovations to market is to secure private sector funding, then compliant testing and ultimately commercialization. This new approach is obtainable because technology has advanced to the point where data can be shared across boundaries.  This sharing accelerates innovations that are works of collaboration between many different companies and organizations. This is exactly what investors want in a business model, and has been successfully used in many industries.

The healthcare sector has operated with a margin of error that can now be reduced by deploying the latest in information systems technologies.  These new advancements enhance an organization’s ability to move new products and procedures through to commercialization more effectively. Data analytics is a great example of technology that has consistently been advancing to the point where stakeholders can fully coordinate intelligent information to better understand the needs of each patient. These stakeholders can realistically implement artificial intelligence, machine learning and other analytic technologies to fill the void and continue to be proactive in helping drive that more comprehensive view of the patient.

This research to personalize the care process is more important than ever because any potential cuts at the federal level will require more efficient use of treatment resources. If doctors can combine data sources at the point of care delivery to more precisely and immediately diagnose and treat illnesses, they can potentially save billions of dollars a year for the healthcare system.

As Harvard Business School’s Clayton Christiansen has said, machine learning is going to happen in a big way in the healthcare provider channel whether the channel likes it or not. The change will happen either through disruptive innovation, a process by which a product or service takes root initially in simple applications at the bottom of a market and then relentlessly moves up market, or through a more gradual evolution that is spurred on by existing stakeholders responding to the changing marketplace. Given those potential budget cuts, stakeholders should plan for disruptions but innovation that will be positive for the healthcare industry.

John A. Kelley, Jr., is Chairman and CEO of CereScan, a functional brain diagnostics company headquartered in Denver.

CereScan’s Latest Patent for its Neuroimaging Database Now Covers All Brain Activity Measurement Methods

CereMetrix CereScan Patent

In response to an application filed with the United States Patent and Trademark Office, CereScan® has broadened the parameters on its automated diagnostic assistance and intelligent support system, CereMetrix®, which uses quantitative measurements to assist in the diagnosis and study of complex brain disorders.  Through award of a second patent, the company may now claim exclusive use of its neuroimaging database systems and methods in the measurement of all types of brain activity.  The patent expands CereScan’s intellectual property and use of its wholly owned data warehouse, known to be the most comprehensive store of functional brain imaging data, associated patient demographic, clinical information and biomarkers worldwide.

“CereScan® is transforming the future of advanced brain diagnostics and use of intelligent learning to benefit those suffering from and studying complex brain disorders,” said John Kelley, CEO and Chairman of CereScan®. “The expansion of our patent allows us to apply key learnings to all manners of brain measurement, and vastly expands the potential for advancements in brain science using technology.”

Read More: CereScan Taps The Ohio State University to Advance Functional Brain Diagnostic System

Headquartered in Denver, CereScan® uses its patented methods, combining patient-clinical information, functional brain imaging and advanced processing software to help medical professionals identify abnormal brain physiology and activity using correlative data and pattern matching contained within its extensive data warehouse.  Through the application of technology to traditional medical practice, CereScan® has assumed a leadership role in advancing precision brain diagnostics and science.  Its first patent was awarded in September of 2014, and allowed for exclusive utilization of it systems and methods under more limited claims.

CereScan® is uniquely positioned to capitalize on a planned release of CereMetrix®, its MAaS (Medical Analytics as a Service) platform in 2017.  Its patented technology is considered by industry insiders to be a positive disruptor in the field of diagnostic radiology.  CereScan’s MAaS product suite incorporated into its CereMetrix® offering is being labeled as revolutionary, based on early feedback from Radiologists, Neurologists, and Psychiatrists who have had a chance to experiment with early release versions.

About CereScan® 
CereScan® combines state-of-the-art brain imaging technologies with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the neurological basis of their conditions. In a variety of legal settings, CereScan provides unbiased evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit http://www.CereScan.com. Connect with CereScan on Twitter @CereScan and on Facebook at Facebook.com/CereScan.

About CereMetrix®

CereMetrix® is an advanced healthcare analytics ecosystem that provides radiologists, practitioners and researchers with precise data about their patient’s brain health. Each new patient’s data will be compared to a library of patients with similar brain patterns, medical histories, and clinical symptoms. The unique brain diagnostic system and ever-expanding data warehouse includes over 7,000 scan encounters, including patients’ medical histories, family histories, symptoms, prior treatments, incoming diagnoses, outgoing diagnoses, and brain scans, among other data points. Each scan is composed of over 262,000 data points that measure activity levels in up to 160 brain regions derived from comparisons to normative data.

CereScan® Extends Brain Diagnostics Services to Southern California

CereScan Southern California

CereScan, a company dedicated to providing advanced brain diagnostics to practitioners and patients, today announced its availability to residents in Southern California. Since 2009, CereScan has used its patented brain evaluation process to help medical providers and their patients find a more complete and accurate diagnosis.

CereScan’s functional brain imaging and analytical services will be offered at Imaging Healthcare Specialists (IHS) through their Encinitas facility near San Diego, California. CereScan is now partnered with nine affiliated clinics across eight states, including its most recent partner at Northwest Community Healthcare in metro Chicago. The addition of IHS expands CereScan’s national functional brain imaging network to provide services to those individuals suffering from a variety of complex, brain-based disorders – ranging from chronic traumatic brain injuries to Alzheimer’s and other dementias to toxic exposure.

“We selected IHS as our next launch partner because of their stellar reputation in the San Diego marketplace, and their use of the highest quality imaging technology. We’ve received multiple requests from across the state from medical professionals and patients seeking our statistically measured brain diagnostics process, and we are thrilled to now be able to offer those services.” said John Kelley, CEO and Chairman of CereScan. “With over 30 years of imaging services experience, IHS’s patient-focused, outpatient center is an ideal relationship.  We are honored to be partnered with them.”

Read More: CereScan Participates in Largest Brain Amyloid Scan Research Study

Headquartered in Denver, CereScan uses its patented process to combine patient clinical information, functional brain imaging and advanced processing software to help provide clarity around complex brain disorders that often have overlapping symptoms. As an example, patients with a traumatic brain injury often experience personality changes, poor concentration and fatigue, which can also be common symptoms for bipolar disorder and dementia.

Through this partnership, IHS has integrated CereScan’s patented process, using qSPECT (quantitative Single Photon Emission Computed Tomography) imaging, to assist referring physicians by clarifying non-specific symptoms to enhance the physician’s ability to accurately diagnose and have better outcomes.

Medical providers and patients interested in pursuing CereScan’s brain diagnostic process can call toll free (866) 722-4806 or email pcc@cerescan.com .

About CereScan® 
CereScan combines state-of-the-art qSPECT, qEEG and PET/CT brain imaging technologies with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the neurological basis of their conditions. In a variety of legal settings, CereScan provides unbiased evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit http://www.CereScan.com. Connect with CereScan on Twitter @CereScan and on Facebook at Facebook.com/CereScan.

About Imaging Healthcare Specialists

Imaging Healthcare Specialists (IHS) is a leading outpatient provider of San Diego medical imaging services, diagnostic imaging, and radiology. Offering over 30 years of imaging services experience, IHS has earned an outstanding reputation for providing the highest quality medical imaging technology, highly specialized expertise and exceptional customer service to physicians and patients. Imaging Healthcare Specialists services southern California, including Riverside County and San Diego County.